The ability of HIV-1 to evolve resistance to antiretroviral drugs leads to treatment failure. By nucleotide sequencing of HIV-1 subtype B isolates, amino acids responsible for drug resistance have been identified. Less information is available, however, on the extent and distribution of these amino acids in HIV-1 nonsubtype B viruses circulating mainly in developing countries. More HIV-infected patients in the developing world are now using antiretroviral drugs, and hence there is a need to monitor drug resistance mutations in HIV-1 nonsubtype B viruses. This study examines the prevalence of drug resistance mutations in 28 antiretroviral drugnaive HIV-1-infected Zambians. HIV-1 proviral DNA was extracted from peripheral blood mononuclear cells. The region encompassing gag p17 to env C2-V3-C3 was amplified by the polymerase chain reaction followed by direct sequencing. Sequence analyses for drug resistance-associated mutations in the protease and reverse transcriptase genes, and HIV-1 subtyping, were done. Overall, 92.8% of the generated sequences were HIV-1 subtype C. The generated sequences revealed only secondary associated, but no primary, drug-resistance mutations. The most frequent secondary mutations in the protease and RT genes were, respectively, I93L (91.7%), L89M (79.2%), M36I/V (79%, 4.2%), and R211K (70.8%), S48T (62.5%). The atypical residues M41N (3.6%) and D67A (3.6%) were detected in the RT gene. This study reveals many naturally occurring polymorphisms in HIV-1 subtype C isolates from antiretroviral drug-naive individuals. Such polymorphisms could lead to rapid treatment failure and development of drug-resistant HIV-1 mutants in individuals undergoing antiretroviral therapy. 151 
ious levels of resistance to specific ARV drugs have been identified through sequence analyses of the HIV-1 subtype B pol region. Several other studies have also reported similar changes among other HIV-1 group M subtypes. [5] [6] [7] [8] [9] [10] Although ARV drugs are becoming more accessible in developing countries, there is a major public health concern that widespread use of these drugs, if not properly managed, may lead to a rapid increase in the prevalence of drug-resistant mutants. This would lead to primary resistance, which has significant implications in the choice of initial ARV therapy. 11 This may be seen to be a major obstacle for effective treatment of HIV-1-infected patients in developing countries. Mutations associated with drug resistance, transmission of resistant HIV-1 mutants, and their prevalence in ARV-naive individuals have been documented for the HIV-1 subtype B viruses predominant in North America and Europe. [12] [13] [14] [15] On the other hand, less information is available on resistant mutants in HIV-1 non-B subtypes from regions other than Europe and North America. Characterization of HIV-1 protease and RT sequences from ARV drug-naive individuals is an important step in understanding the genetic correlates of drug resistance in the HIV-1 non-B subtypes.
HIV-1 subtype C has been reported to be the most prevalent subtype in Zambia. [16] [17] [18] In Zambia, ARV drugs are accessible to few HIV-1-infected individuals. Pregnant women have been recruited into the HIV-1 Mother-to-Child Transmission (MTCT) Study. In addition, the government of the Republic of Zambia is making efforts to have the ARV drugs made accessible to many HIV-infected patients countrywide. Routine drug resistance testing is not available in Zambia. Furthermore, there has been no report from Zambia on HIV-1 pol genes obtained from ARV-naive HIV-1-infected patients. The objective of this study was therefore to characterize the polymorphic patterns found in the protease and RT regions of HIV-1 subtype C isolates from such individuals.
Kanyama Health Center in Lusaka, Zambia, was selected as the study site. Blood was collected from expectant women attending the Kanyama antenatal clinic for the first time. The study inclusion criteria were as follows: (1) residence within the community surrounding the study center, (2) no previous history of having taken an HIV test, (3) no evidence of clinical disease on physical examination, (4) no history of travel abroad during the preceding year, and (5) ability to give informed consent. Venous blood samples were obtained from 90 antenatal attendants during the month of August 2000. The average age of these women was 24.9 years (range, 18-38 years).
HIV-1 antibody tests were done with Bionor HIV-1/2 (Bionor, Skien, Norway) and enzyme immunoassay (EIA) (Murex VK 56 HIV-1; Biotech Limited, Kent, UK) kits, according to the manufacturer instructions. Indeterminate results were subjected to a Western blot assay (HIV Blot 2.2; Genlabs Diagnostics, Singapore). Of the 90 whole blood samples collected from pregnant women whose HIV status was unknown, 28 (31%) were HIV-1 seropositive. The date of infection could not be determined at the time of recruitment. However, all the patients were clinically asymptomatic at the time of specimen collection. The risk factor for HIV-1 infection for all cases was heterosexual contact.
The 28 HIV-1-seropositive samples were analyzed for the prevalence of drug resistance mutations and HIV-1 subtypes. Extraction of DNA was done as described previously. 17 Briefly, peripheral blood mononuclear cells (PBMCs) were separated A from ethylenediaminetetraacetic acid (EDTA)-treated blood by Ficoll/Hypaque density centrifugation. Cell pellets of the uncultured PBMCs were digested with proteinase K and sodium dodecyl sulfate (SDS) for DNA extraction, using the phenol-chloroform method. The DNA was precipitated with 100% cold ethanol in the presence of 0.25 M ammonium acetate and then centrifuged. The DNA pellets were washed and resuspended in 25 ml o sterile distilled water.
The extracted DNA was subjected to an initial polymerase chain reaction (PCR) for a 5-kb fragment encompassing the gag and pol regions, using FGF60 and FGR53 primers as described previously. 19 This was then followed by individual amplification of gag, protease, and RT fragments from the initial PCR products. The 374-bp protease fragment was amplified with modified primers described previously (W. Sugiura, personal communication). The primer sequences were as follows: . Subtyping was also done with sequences from the gag p17 and env C2-V3-C3 regions, which were amplified with primer sets described previously. 17, 20 Approximately 300 ng of extracted DNA was used to amplify the 5-kb fragment in a 100-ml PCR volume. Ten microliters of the PCR product was then used in a total 50-ml PCR volume, to amplify the protease, RT, gag p17, or env C2-V3-C3 fragment in the first round. Five microliters of the firstround product was subsequently used in a 100-ml PCR volume in the second round. A PCR volume contained 2 mM Tris-HCl (pH 8.0), 10 mM KCl, 0.01 mM EDTA, 0.1 mM dithiothreitol (DTT), 0.05% Tween 20, 0.05 or 5% glycerol, dNTP mixture (0.4 mM each), primers (1 pM each), and 2.5 units of LA Taq polymerase (TaKaRa Shuzo, Tokyo, Japan). The cycling conditions for the first round were as follows: 94°C for 2 min followed by 35 cycles with 1 min at 94°C, 1 min at 47°C, and 4 min at 72°C, and a final extension for 7 min at 72°C. The second round of the PCR profile had 25 cycles with the same cycling conditions described above.
The amplified proviral HIV-1 fragments in a total volume of 95 ml were ethanol precipitated and then recovered from a 1.5% ethidium bromide-stained agarose gel, using a QIAquick PCR purification kit (Qiagen, Chatsworth, CA) according to the manufacturer instructions. Sequences were generated directly from the amplified PCR products without intermediate cloning, using the ABI Prism BigDye terminator cycle sequencing Ready Reaction kit (PE Applied Biosystems, Foster City, CA) with an ABI Prism 310 genetic analyzer (PE Applied Biosystems). Se- 
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Abbreviations: NA, Sequence was not available for analysis; -, no mutation shown in the protease gene for the respective sequences.
a Total number of secondary mutations at positions previously characterized as associated with drug resistance for each HIV-1 isolate is shown in parentheses.
HIV-1 subtype
quence products were purified with Centri-Sep columns (PE Applied Biosystems) before loading onto the ABI Prism 310 genetic analyzer. Respective internal primers were used in sequencing the protease, RT, gag p17, and env C2-V3-C3 regions under the following conditions: 96°C for 10 sec, 50°C for 5 sec, and 60°C for 4 min for 25 cycles. By bidirectional sequencing, each nucleotide position in the respective fragments was analyzed by independent sequence reactions.
Sequences were manually edited and the GENETYX-MAC 7.3 package (Software Development, Tokyo, Japan) was used to predict the amino acid sequences. To determine the prevalence of amino acid polymorphisms at positions previously characterized as drug resistance mutation sites, 21, 22 99 and 200 amino acid residues of each isolate deduced from the nucleic acid sequences of the protease (positions 2253-2549, i.e., 297 bp) and RT (positions 2670-3269, i.e., 600 bp) regions, respectively, were compared with the subtype B consensus sequence from the Stanford HIV RT and Protease Sequence Database (http://hivdb.stanford.edu) for mutations associated with resistance to PIs and RTIs. The results were also compared with published data on HIV-1 subtype C isolates obtained from ARV-naive individuals. 6, 7, 9, 10, 23, 24 We obtained protease gene sequences for 25 of the 28 study subjects. All sequences showed a full-length open reading frame. Figure 1A shows the alignment of the generated protease gene amino acid sequences compared with a subtype B consensus sequence from the database. No primary mutations (D30N, M46I, G48V, I50V, V82A/F/T/S, 184V, and L90M) conferring resistance to the currently used PIs were detected. Secondary mutations were, however, detected in all 25 test sequences, with an average mutation number of 4.5 (range, 3-6). Five sequences (20%) had six mutations, seven (28%) had five mutations, seven (28%) had four mutations, and six (24%) had three mutations each (Table 1) . Among secondary mutations detected at 12 positions, the prevalence of I93L, L89M, M36I/V, S/D37N, and E35D substitutions exceeded 50%, in descending order. At some positions known for amino acid mutations associated with drug resistance, the following unusual amino acid substitutions were observed: M36T (n 5 1), L63S (n 5 1), and L63T (n 5 1). At eight positions, amino acid residues (12S, 15V, 19I, 36I, 41K, 69K, 89M, and 93L) differed from those in the subtype B consensus sequence. These residues represent the consensus in HIV-1 subtype C.
The majority protease consensus sequence derived from the generated sequences was compared with the subtype C HIV-1 protease consensus sequence from the Los Alamos HIV database (http://hiv-web.lanl.gov) for polymorphism. The two consensus sequences were found to be identical at all positions (data not shown). There were 22 (22.2%) polymorphic and 77 (77.8%) conserved positions among the test sequences. No consensus residues occurred with frequencies of more than 10% at 11 positions (residues 12, 15, 16, 19, 35, 36, 37, 41, 63, 74, and 89) and less than 10% at 11 positions (residues 13, 14, 17, 20, 43, 60, 61, 64, 70, 79, and 93). The greatest number of amino acid variations was detected at position 63 (L, A, P, T, S, and V), followed by position 36 (I, L, M, T, and V). Similar polymorphisms have been observed at position 63 in HIV-1 subtype B and nonsubtype B isolates from untreated persons, but more variants at position 36 have been detected in this study.
12,13,15,23
We obtained RT gene sequences from all 28 subjects. Amino acid alignment of codons 41 to 240 of these sequences and HIV-1 subtype B RT consensus sequence from the database is shown in Fig. 1B . No primary mutations conferring resistance to the currently used NRTIs and NNRTIs (E44D, K65R, T69D, K70R, L74V, V118I, Q151M, M184V, or T215Y and K103N, V106A, V108I, Y181C/I, Y188C/L/H, or G190A/S, respectively) were detected in any of the sequences. Twenty-five of 28 (89.3%) sequences bore secondary mutations related to NRTI drug resistance, with an average mutation number of 1.5 (range, 1-3). Nine (36%) sequences had three mutations, nine (36%) had two mutations, and seven (28%) had one mutation each (Table 1) . Among secondary mutations detected at nine positions, the prevalence of R211K and S48T substitutions exceeded 50%, in descending order. Atypical mutations detected at positions known for primary resistance were M41N (n 5 1) and D67A (n 5 1). At six positions the amino acid residues (48T, 122E, 173A, 177E, 200A, and 211K) differed from those in the subtype B consensus sequence. These residues represent the consensus in HIV-1 subtype C.
A comparison of the majority RT consensus sequence with the HIV-1 subtype C RT consensus sequence (Los Alamos database) revealed the two to be identical at all positions (data not shown). Polymorphic and conserved amino acid residues were detected at 46 (23%) and 154 (77%) positions, respectively. Unlike in the protease gene, all nonconsensus residues occurred with a frequency of less than 10%. At six positions (residues 48, 50, 123, 173, 211, and 207) nonconsensus residues occurred with a frequency of 5 to 8.5%. At 15 and 23 positions, nonconsensus residues occurred with a frequency of 1-3.3 and 0.5%, respectively. The greatest number of amino acid variations was detected at position 207 (E, A, D, M, N, R, S, and V), followed by position 123 (D, A, E, G, N, and S).
To determine the HIV-1 subtypes, 25, 28, 28, and 28 generated amino acid sequences of protease, RT, gag p17, and env C2-V3-C3 respectively, together with reference amino acid sequences representing HIV-1 subtypes A, B, C, D, F, G, H, J, and K obtained from the Los Alamos reference database (http://hiv-web.lanl.gov), were aligned with the CLUSTAL W multiple alignment program, 25 and neighbor-joining trees were generated. Diagrams were drawn with the Tree View program. The alignment and phylogenetic analysis revealed that 26 of the 28 (92.8%) subjects were infected with HIV-1 subtype C. One (3.6%) was HIV-1 subtype A, and another (3.6%) was recombinant HIV-1 subtype A in env gp120 and subtype C in protease, RT, and gag p17 (A/C) ( Table 1 ). The predominance of HIV-1 subtype C in Lusaka has previously been reported. 17, 18 Figure 2 shows distinct clustering of the amino acid sequences with reference sequences in the protease, RT, env C2-V3-C3, and gag p17 regions. Three sequence sets, 4739/4761, 4764/4752/4796, and 4746/4757, had identical amino acid sequences in the protease region ( Fig. 2A) . To exclude the possibility of contamination, we confirmed the nucleotides of these sequences by sequencing the products of two PCR amplifications, and further determined their heterogeneity at the nucleotide level by pairwise comparison of sequences in each set. Protease, RT, env C2-V3-C3, and gag p17 nucleotide sequences (297, 600, 279, and 390 bp, respectively) for the 4746/4757 set were compared. Only protease sequences (297 bp) for the 4739/4761 and 4764/4752/4796 sets were compared because
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these did not cluster together in the RT, env C2-V3-C3, and gag p17 regions (Fig. 2B-D, respectively) . Several polymorphic sites sharing synonymous mutations were detected in each of the paired sequences of the latter two sequence sets. Nonsynonymous mutations were not detected. On the other hand, nucleotide sequences 4746 and 4757 were identical in the protease region and had a homology level of 99.5% in both the RT and gag p17 regions, and 76.9% in env C2-V3-C3. Three polymorphic sites were observed in the RT region, of which two were shared nonsynonymous mutations resulting in different amino acid residues at positions 48 and 204. Three polymorphic sites were also observed in the gag p17 region. Two of these were shared synonymous mutations whereas one was nonsynonymous. Because of the high homology of amino acid sequences 4746 and 4757 in the RT and gag p17 regions (99% and 99.2% respectively), they clustered together in the phylogenetic trees with bootstrap values of 77 and 100%, respectively ( Fig. 2B and C) . However, these sequences did not cluster together in the env C2-V3-C3 phylogenetic tree (Fig. 2C) because of their high divergence in the C2 and C3 sequences. In the env V3 loop, 34 amino acid residues between these two sequences were identical but differed at position 29. All seven HANDEMA ET AL. 156
FIG. 2.
Unrooted phylogenetic tree analysis of 25 HIV-1 protease (A), 28 HIV-1 reverse transcriptase (B), 28 HIV-1 env C2-V3-C3 (C), and 28 HIV-1 gag p17 (D) amino acid sequences (boxed) generated from the subjects in conjunction with HIV-1 subtype reference sequences. Sequences were subjected to alignment by the CLUSTAL W program for the Power Macintosh. The introduced gaps in the alignment of RT, gag p17, and env C2-V3-C3 sequences were gap stripped before analysis. Neighbor-joining trees were constructed with 100 bootstrap replications of the Kimura two-parameter distance matrix to evaluate the robustness of the phylogenetic relationship between sequences. HIV-1 group O subtypes were used as an outgroup. Bootstrap values exceeding 75% are indicated at the respective branch nodes. The scale bar indicates the evolutionary distance of 10% nucleotides per position in the sequences.
sequences (4739, 4746, 4752, 4757, 4761, 4764, and 4796) are HIV-1 subtype C-like in the gag p17, protease, RT, and env C2-V3-C3 regions. Five of these (4739, 4752, 4761, 4764, and 4796) have identical protease sequences and clustered together in Fig. 2A, yet were not related in the RT, env C2-V3-C3, and gag p17 regions. Two sequences (4746 and 4757) were related in three regions but not in one. In the absence of laboratory contamination, we speculate that the amplified HIV-1 sequences from these seven samples are HIV-1 intrasubtype C recombinants. Full genome analysis of these HIV isolates is, how-
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FIG. 2. (continued)
ever, required for verification. In the case of sequence samples 4746 and 4757, it could be that one of the women was infected with more than one strain of HIV-1 subtype C. There is also a possibility of epidemiological linkage of transmission between these two women, that is, from man to both women, or from one woman to man and then to the other woman. We have noted some recombinant sequences in our molecular surveillance of HIV-1 in Zambia (data not published). Further studies to determine HIV-1 recombinations in Zambia are therefore needed. We present for the first time the prevalence of drug resistance-associated mutations in HIV-1 isolates from Zambia. We did not detect any primary mutation conferring resistance to PIs, NRTIs, or NNRTIs in this study. This reflects the lack of widespread usage of ARV drugs in Lusaka, Zambia, and Kanyama Township in particular. Furthermore, none of the study subjects would have been receiving ARV drug therapy because they had not known their HIV status before this study. In contrast with the absence of primary mutations, many substitutions that have been described as secondary mutations in the protease-and RT-coding gene regions were found in these samples. Our findings reveal that all the HIV-1 strains in the study bore secondary mutations in the protease gene and 89.3% bore such mutations in the RT region analyzed. This indicates that secondary mutations occur as natural polymorphisms more commonly in the protease gene than in the RT gene of HIV-1 subtype C strains. This might suggest that in individuals infected with HIV-1 subtype C and undergoing treatment PI resistance mutants might appear earlier than NRTI or NNRTI resistance mutants. The secondary mutations observed in this study in the protease gene were those associated mainly with HANDEMA ET AL. 158 6 Cane et al. 7 Grossman et al. 9 Pieniazek et al. 23 
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resistance to nelfinavir, indinavir, and ritonavir in the presence of other protease resistance mutations. 21, 22 Secondary mutations observed in the RT gene are those associated with resistance mainly to zidovudine (AZT) in the presence of other RTI resistance mutations. 22 The absence of known primary drug resistance mutations in the protease and RT genes of subtype C HIV-1 isolates in this study and others [6] [7] [8] [9] [10] 23, 26 suggest that these mutations do not occur as natural polymorphisms in this HIV-1 subtype in ARVnaive individuals. The lack of naturally occurring primary resistance mutations in subtype C HIV-1 isolates has been reported elsewhere, where it was shown that subtype C HIV-1 isolates are susceptible to ARV drugs in vitro like wild-type subtype B HIV-1 isolates 6, 10, 27 and that individuals newly infected with subtype C HIV-1 had a virological response similar to those infected with non-resistant subtype B HIV-1 strains. 8 Table 2 shows a comparison of frequencies of secondary mutations with other published data. 6, 7, 9, 10, 23 The frequencies of mutations at positions associated with drug resistance in the RT gene show no similarities in different studies. On the other hand, mutations of residues at positions 36, 89, and 93 in the protease gene in different studies have been detected in almost all isolates and the frequencies are not significantly different. Although these residues form part of the HIV-1 subtype C consensus sequence, they were reported to occur in combination with other mutations in ARV drug-naive patients failing therapy, 8 implying that they may have a profound effect on drug resistance in HIV-1 subtype C. In other HIV-1 subtypes, these mutations were reported to occur at much lower frequencies, except the mutations at position 36 in HIV-1 subtype A, where they have been reported to occur at comparatively high frequencies as in HIV-1 subtype C. 6, 7, 9, 12, 15, 23, 26 Secondary mutations associated with resistance to PIs and NRTIs were detected but none were seen for NNRTIs. It is not yet clear what impact various combinations of the many preexisting secondary mutations in HIV-1 subtype C isolates from ARV-naive patients might have on therapy. It was reported that in many patients who were infected with HIV-1 subtype C and failing therapy, primary mutations were preferentially induced in addition to the mutational patterns observed in ARV drugnaive individuals. 8 A consequence of the many preexisting secondary mutations might therefore be an early emergence of ARV-resistant mutants. Mutational patterns that may develop as more people infected with HIV-1 subtype C begin using ARV drugs will need to be investigated further. The ongoing MTCT Study in Zambia is using AZT and nevirapine as monotherapy to reduce mother-to-child transmission of HIV. The drug resistance mutational patterns that may develop and their impact on the expected outcome in this study need to be investigated. Baseline genotyping of treatment-naive individuals and continued resistance testing are required, as therapies may need to be adjusted to the local gene profiles for therapeutic and economic benefits.
